Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Pharma: Knocking at global doors - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Dec 24, 2003

    Pharma: Knocking at global doors

    The year 2003 was a very special year for India. Good monsoons, outsourcing opportunities and higher GDP growth projections contributed towards building a 'feel good factor' towards India Inc. The stock markets too caught up with this sentiment. After languishing around the 3,000 levels, markets made gains of more than 2,000 points during the year. The most significant aspect of the current bull run was that it was broad based rather than being sector specific. Thus, we had many sectoral indices like the BSE-Healthcare index outperforming the BSE-Sensex during the year. To get a better perspective, take a look at the following graph.

    As can be seen from the above graph, Rs 100 invested in BSE-Sensex and BSE-Healthcare index on 1st January '03 would have been worth Rs 156 and Rs 187 respectively on December 10, 2003. Thus we see that the pharma industry has managed to outperform the Sensex. The reason for the same could be an excellent performance by the pharma companies and an improvement in the prospects of the industry going forward.

    The domestic pharma industry started the year on a very weak note. The VAT fiasco and the truckers strike affected sales in the domestic market during the first quarter of the calendar year. This was followed by a general slump in anti-infectives (largest therapeutic segment), which even recorded negative growth in one month. Consequently, growth in the domestic pharmaceutical markets stagnated during the first half of 2003. Subsequently however, with good monsoons and a revival in the anti-infectives segment, the domestic pharmaceutical industry came back on track once again recording double-digit growth.

    While growth in the domestic markets suffered, revenues form the international markets continued to record strong growth. Indian pharma companies registered impressive growth not only from the regulated markets from sale of generics drugs but also from unregulated markets. However, outsourcing is turning out to be the next big story for domestic pharma companies. The extent of optimism towards outsourcing opportunities awaiting the domestic pharma companies is evident from the fact the top two companies (on the basis of stock price appreciation - See table below) - Divis Laboratories and Matrix Laboratories, both are actively pursuing outsourcing opportunities in contract manufacturing. Lupin, on the other hand made it to the winners list following the initiatives taken by its promoters to settle the inter-group loans. However, investors need to note her that Lupin was one of the stocks that were heavily speculated during the 2000 stock market scam. In general, the upswing in mid-cap stocks in general and mid-cap pharma stocks in particular, resulted in companies like Lupin, Fulford (India) and Aurobindo Pharma to make it into the winners list.

    The winners…
    (Rs) 1st Jan '03 10th Dec '03 Change
    Divis Laboratories 176* 1,292 633%
    Matrix Laboratories 195 1,303 569%
    Lupin Ltd 145 765 427%
    Fulford (I) 97 380 292%
    Aurobindo Pharma 106 379 259%
    *Price as on 12th March '03

    The dream run on the bourses that pharma companies have had in 2003 has ensured that there were no major losers in this sector. However, there were some laggards that under performed not only the BSE-Healthcare index, but also the Sensex. In view of the strong performance shown by midcap pharma stocks, it is not surprising to see that the companies that made it to the laggards list are all big companies.

    The laggards…
    (Rs) 1st Jan '03 10th Dec '03 Change
    Cipla 902 1,219 35%
    Novartis 277 381 37%
    Pfizer India 383 527 38%
    Dr Reddy's 922 1,388 51%
    Wockhardt 450 715 59%

    Among the laggards, all the five companies gave disappointing quarterly results. Cipla was the worst performer in the pharma sector. In case of Cipla, while topline recorded impressive growth, margin pressure ensured that the company's bottomline remained stagnant. Novartis, on the other hand, in view of intense competition from generics players, reported not only stagnancy in net sales but also declining margins. Pfizer's performance was affected due to the delay in its merger with Park-Davis and negative growth registered by its top brands. In case of Dr Reddy's Laboratories, the stock suffered in view of the uncertainty regarding the launch of 'Amlodipine Maleate' and consequent absence of any major launch in the near term. Finally, Wockhardt was plagued with a host of problems, first its dispute with FMRAI followed by the VAT fiasco, which significantly affected its performance.

    What to expect?

    Although 2003 started on a rather timid note, it has certainly ended on a very strong note. However, will this upswing continue in the next year? As far as the domestic markets are concerned, good monsoons signal a revival in the domestic markets, which are once again recording double-digit growth. Recently the Indian Patent Office granted exclusive marketing rights (EMR) to two pharma companies. This coupled with the fact that the cabinet has approved a third amendment to The Patent Act, providing for product patents, removes doubts regarding government's commitment towards accepting the TRIPS agreement. This is a big positive for the MNC pharma companies as they will be able to launch products from their parent's portfolio under patent protection. Resultantly, the performance of these MNC pharma companies will get a fillip.

    On the exports front, the US government has taken various policy decisions like inclusion of generics drugs in its Mediclaim policy and has also eased the process of introduction of generics in the market. Given the fact that larger domestic pharmaceutical companies like Ranbaxy and Dr Reddy's Laboratories already have a presence in the US markets and their strong re-engineering skills and manufacturing capabilities, they are in a very good position to generate revenues from the US generics market. Meanwhile, in view of India's expertise in manufacturing and given the fact that India has the highest number of US-FDA approved plants outside the US, outsourcing opportunities will continue to drive growth for Indian companies. However, here India will face competition from other countries like China.



    Equitymaster requests your view! Post a comment on "Pharma: Knocking at global doors". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    The Power of 5 Minutes (The 5 Minute Wrapup)

    Jun 16, 2017

    Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 18, 2017 (Close)